Communication and optimal hierarchical networks

We study a general and simple model for communication processes. In the model, agents in a network (in particular, an organization) interchange information packets following simple rules that take into account the limited capability of the agents to deal with packets and the cost associated to the existence of open communication channels. Due to the limitation in the capability, the network collapses under certain conditions. We focus on when the collapse occurs for hierarchical networks and also on the influence of the flatness or steepness of the structure. We find that the need for hierarchy is related to the existence of costly connections.Comment: 7 pages, 2 figures. NATO ARW on Econophysic

Large-Eddy Simulation of Turbulent Flames in Syn-Gas Fuel-Air Mixtures

Combustion characteristics of synthetic gaseous fuels (H2 and CO mixture) have been investigated in laminar and turbulent flow congurations with special emphasis on flame structure and propagation characteristics of CO-rich and H2-rich premixed flames. Two reduced CO H2 mechanisms (10-step and 5-step) are first investigated and it is shown that the 10-step mechanism is quite accurate over a wide range of equivalence ratios and with and without CO2 dilution. The 10-step mechanism is then used for both laminar and turbulent premixed flame calculations of both CO-rich and H2-rich mixtures. The effect of a single isolated vortex interacting with a laminar flame and of a pair of counter rotating vortices with a turbulent premixed \ud flame front are investigated for different turbulence levels. It is shown that H2 reaction zone is much thinner than the CO reaction zone, and that they do not overlap physically. Under certain conditions, the H2 reaction rate contours can become broken even when the CO reaction rate contours remains contiguous. Flame structure and propagation (burning) speed are substantially different depending upon the syn-gas (COH2) composition. Flame-vortex interaction creates large-scale flame wrinkling, the scale of which also depends on the initial fuel composition. Flame-vortex interactions also causes local enhancement and dissipation of vorticity depending on the local baroclinic torque and dilatation effects

Sympathectomie thoracique pour hyperhidrose palmo-axillaire, Y a-t-il une place pour l\u2019utilisation du bisturi ultrasonique par toracoscopie?

Traitement de l'hyperhidrose palmaire par thoracoscopie \ue0 l'aide des ultrasons

E-Health Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress : Nice, France, March 22-23, 2019

Altres ajuts: ALCOTRA Program (Alpes Latines COopération TRAnsfrontalière).By definition, neuromuscular diseases are rare and fluctuating in terms of symptoms; patients are often lately diagnosed, do not have enough information to understand their condition and be proactive in their management. Usually, insufficient resources or services are available, leading to patients' social burden. From a medical perspective, the rarity of such diseases leads to the unfamiliarity of the medical staff and caregiver and an absence of consensus in disease assessment, treatment, and management. Innovations have to be developed in response to patients' and physicians' unmet needs. It is vital to improve several aspects of patients' quality of life with a better comprehension of their disease, simplify their management and follow-up, help their caregiver, and reduce the social and economic burden for living with a rare debilitating disease. Database construction regrouping patients' data and symptoms according to specific country registration on data privacy will be critical in establishing a clear consensus on neuromuscular disease treatment. Clinicians also need technological innovations to help them recognize neuromuscular diseases, find the best therapeutic approach based on medical consensus, and tools to follow patients' states regularly. Diagnosis also has to be improved by implementing automated systems to analyze a considerable amount of data, representing a significant step forward to accelerate the diagnosis and the patients' follow up. Further, the development of new tools able to precisely measure specific outcomes reliably is of the matter of importance in clinical trials to assess the efficacy of a newly developed compound. In this context, creation of an expert community is essential to communicate and share ideas. To this end, 97 clinicians, healthcare professionals, researchers, and representatives of private companies from 9 different countries met to discuss the new perspective and challenges to develop and implement innovative tools in the field of neuromuscular diseases

E-Health Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019

By definition, neuromuscular diseases are rare and fluctuating in terms of symptoms; patients are often lately diagnosed, do not have enough information to understand their condition and be proactive in their management. Usually, insufficient resources or services are available, leading to patients' social burden. From a medical perspective, the rarity of such diseases leads to the unfamiliarity of the medical staff and caregiver and an absence of consensus in disease assessment, treatment, and management. Innovations have to be developed in response to patients' and physicians' unmet needs. It is vital to improve several aspects of patients' quality of life with a better comprehension of their disease, simplify their management and follow-up, help their caregiver, and reduce the social and economic burden for living with a rare debilitating disease. Database construction regrouping patients' data and symptoms according to specific country registration on data privacy will be critical in establishing a clear consensus on neuromuscular disease treatment. Clinicians also need technological innovations to help them recognize neuromuscular diseases, find the best therapeutic approach based on medical consensus, and tools to follow patients' states regularly. Diagnosis also has to be improved by implementing automated systems to analyze a considerable amount of data, representing a significant step forward to accelerate the diagnosis and the patients' follow up. Further, the development of new tools able to precisely measure specific outcomes reliably is of the matter of importance in clinical trials to assess the efficacy of a newly developed compound. In this context, creation of an expert community is essential to communicate and share ideas. To this end, 97 clinicians, healthcare professionals, researchers, and representatives of private companies from 9 different countries met to discuss the new perspective and challenges to develop and implement innovative tools in the field of neuromuscular diseases